Overview

Reno- and Vascular Protective Effect of a Vitamin-D-analogue in Moderate to Severe Chronic Kidney Disease

Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
0
Participant gender:
All
Summary
Recently it has been documented that vitamin D has important functions in the human body that are unrelated to its primary effects in calcium homeostasis and bone mineralization. In clinical studies, paricalcitol - a low-calcemic vitamin D analogue - has been shown to decrease proteinuria, a marker of disease progression and cardiovascular risk in patients with chronic kidney disease (CKD). The purpose of this study is to investigate the effect of a paricalcitol on renal and cardiovascular variables in patients with moderate to severe CKD.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Erling Bjerregaard Pedersen
Treatments:
Ergocalciferols
Vitamin D
Vitamins
Criteria
Inclusion Criteria:

- Kidney disease corresponding to eGFR: 15-59 ml/min

- Albuminuria > 30 mg/l

Exclusion Criteria:

- Total parathyroidectomy

- Diabetes Mellitus

- Cancer

- Illicit drug or alcohol abuse

- Pregnancy og nursing

- Ongoing NSAID or corticosteroid treatment

- b-hemoglobin < 6 mmol/l

- p-albumin < 25 mmol/l

- Clinically significant hypercalcemia

- Office blood pressure > 170/105 mmHg that despite antihypertensive treatment still is
> 170/105 mmHg when using home blood pressure measurements or 24-hour ambulatory blood
pressure measurement.